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Abstract
The expression of protein-coding genes requires the selective role of many transcription factors, whose coordinated actions
remain poorly understood. To further grasp the molecular mechanisms that govern transcription, we focused our attention
on the general transcription factor TFIIH, which gives rise, once mutated, to Trichothiodystrophy (TTD), a rare autosomal
premature-ageing disease causing inter alia, metabolic dysfunctions. Since this syndrome could be connected to
transcriptional defects, we investigated the ability of a TTD mouse model to cope with food deprivation, knowing that
energy homeostasis during fasting involves an accurate regulation of the gluconeogenic genes in the liver. Abnormal
amounts of gluconeogenic enzymes were thus observed in TTD hepatic parenchyma, which was related to the
dysregulation of the corresponding genes. Strikingly, such gene expression defects resulted from the inability of PGC1-a to
fulfill its role of coactivator. Indeed, extensive molecular analyses unveiled that wild-type TFIIH cooperated in an ATP-
dependent manner with PGC1-a as well as with the deacetylase SIRT1, thereby contributing to the PGC1-a deacetylation by
SIRT1. Such dynamic partnership was, however, impaired when TFIIH was mutated, having as a consequence the disruption
of PGC1-a recruitment to the promoter of target genes. Therefore, besides a better understanding of the etiology of TFIIH-
related disease, our results shed light on the synergistic relationship that exist between different types of transcription
factors, which is necessary to properly regulate the expression of protein coding genes.
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Introduction
In response to various physiological signals, selective and
combined actions of a number of transcription factors modulate
the expression of protein-coding genes [1]. In eukaryotes, the
combinatorial use of hundreds of proteins is required for the
synthesis of a single messenger RNA by the RNA Polymerase II
(RNA Pol II) in association with the general transcription factors
TFIIA, B, D, E, F and H [2]. Such number of protagonists
requires dynamic networks to coordinate their actions during
transcription. This is notably the case when a critical physiological
parameter as glycaemia must be preserved within a narrow range.
Indeed, to avoid the deleterious effects of hypo or hyperglycemia,
the organism maintains steady circulating glucose levels, providing
glucose for cells dependent on this fuel, such as neuronal and red
blood cells. Apart from modulation of enzymes activity through
posttranslational modifications and allosteric controls, some
transcriptional regulations of rate limiting enzymes are intimately
involved in maintaining blood glucose levels. Such transcriptional
control is fundamental in the liver, which plays a central role in
integrating signals of several cell types and multiple metabolic
pathways. In particular, during starvation, in response to
physiological signals like glucagon and glucocorticoids, hepatic
gluconeogenic genes (such as the phosphoenolpyruvate carboxyki-
nase Pepck and the glucose-6-phosphatase G6Pase) are regulated
through the selective action of many transcription factors [3],
including cAMP-responsive element binding protein (CREB) [4]
in association with the CREB-regulated transcription coactivator 2
(CRTC2/TORC2) [5], CCAAT enhancer-binding protein (C/
EBP) [6], Forkhead O box 1 (FOXO1) [7,8], hepatocyte nuclear
factors (especially HNF-4a) [9] and the glucocorticoid receptor
(GR) [10,11]. The transactivation mediated by these transcription
factors is potentiated synergistically by different coactivators, such
as the peroxisome proliferator-activated receptor-a coactivator 1
(PGC-1a). Interestingly, although its role on gluconeogenic gene
remains unclear [12,13], PGC-1a gene expression during fasting is
rapidly induced in mouse liver, concomitantly with PEPCK and
G6Pase up-regulation [14,15]. Strikingly, PGC-1a activity is
closely dependent to its deacetylation by the energy sensor SIRT1
(silent mating type information regulation 2 homolog 1), which is
stimulated by the intracellular NAD+ and indirectly by pyruvate
high concentrations related to starvation [15,16].
Many transcription factors have been identified during the
fasting-induced expression of gluconeogenic genes, but little is
known about their cooperative interactions with the general
transcription machinery. Among the basal transcription factors,
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TFIIH plays a pivotal role during transcription by interacting with
different factors including nuclear receptors [17]. TFIIH, which is
also intimately implicated in the nucleotide excision repair (NER)
pathway, is a multienzymatic protein complex that can be resolved
into two subcomplexes: the core (containing the helicase XPB,
p62, p52, p44, p34 and TTDA) and the cdk-activating kinase
complex (CAK, containing MAT1, CYCLIN H and the cyclin-
dependent kinase CDK7). While the helicase XPD subunit, which
bridges the CAK to the core of TFIIH, mainly functions in NER
[18], the XPB helicase catalyzes DNA unwinding around the
transcription initiation site and contributes to the promoter escape
by RNA pol II [19]. In addition, TFIIH owns a kinase activity (via
its CDK7 subunit) that contributes to transcription initiation by
phosphorylating the C-terminal domain (CTD) of the RNA pol II
largest subunit [20]. The phosphorylation by CDK7 is also
required for the optimal transactivation mediated by different
nuclear receptors, such as the peroxisome proliferator activated
receptors PPARs [21] and the thyroid hormone receptors TR
[22].
The key role played by TFIIH is illustrated by the fact that several
mutations in its XPB, XPD and TTDA subunits lead to the rare
autosomal recessive disorders Xeroderma Pigmentosum (XP),
sometimes associated with Cockayne syndrome (XP/CS), and
Trichothiodystrophy (TTD). Besides photosensitivity and skin
cancers, these patients can exhibit a large spectrum of clinical
abnormalities, including skeletal defects, mental retardation,
immature sexual development and dwarfism. To gain more insight
into these complex clinical symptoms, mouse models bearing
TFIIH mutations found in patients have been generated. In
particular, the TTDmouse model (having the most common XPD/
R722W point mutation found in TTD patients) [23] develops a
phenotype similar to what observed in patients [24] including,
beside the typical dry and brittle hairs [25], progressive cachexia
and hypoplasia of the adipose tissues [26]. TTD mice weight loss is
not related to aberrant food uptake or intestinal malabsorption [21],
and analysis of blood cell parameters of adult mice only revealed a
mild normochromic anaemia and decreased levels of branched-
chain amino acids that were potentially related to starvation [24].
TTD mice thus suffer from progressive failure to thrive, which is
likely to be the cause of premature death, but the major cause of this
failure is unknown. Although TTD has been defined at first as a
DNA repair syndrome [27], transcriptional impairments may have
a role in the development of TTD phenotypes [17]. In this regard, it
has been shown that PPARc dysfunction contributes to the
hypoplasia of the adipose tissues [21]. However, the pleiotropic
nature of the TTD phenotypes might imply combinational defects
of other additional transcription factors.
To study the transcriptional defects that might occur in TFIIH
related diseases, TTD mice were subjected to different fasting
periods. According to the fact that the physiological adaptation to
fasting requires accurate genes regulation in the liver, the hepatic
response to starvation of TTD mice was particularly studied.
Taken together, our results show that TTD mutation disrupts the
dynamic partnership between TFIIH, SIRT1 and PGC-1a, thus
impeding the PGC-1a deacetylation by SIRT1 and consequently
the correct expression of gluconeogenic genes.
Results
Effects of food withdrawal in TTD mice
While TTD mice suffer from progressive failure to thrive, the
young adults mice did not yet develop severe metabolic
alterations when normally fed [21,24](ref therein). Having
observed that the daily food intake was identical between 3-
months-old WT and TTD mice (Figure 1A), the two lines have
been then subjected to different periods of fasting (24 and
48 hours). While the body weight was progressively decreased in
both strains (Figure 1B), the liver weight was reduced in WT and
TTD mice after 24 hours (reduction of 14.4%66.5% in WT and
17.3%63.6% in TTD, respectively), followed by a higher
reduction in TTD mice, losing almost 40% (39.8%69.2%) of
the weight after prolonged fasting (48 hours) (Figure 1C).
Different serological analyses were performed and revealed slight
differences after starvation between the two strains, especially for
triglycerides, free fatty acids and ketones bodies (as illustrated by
b-hydroxybutyrate) (Figure 1E, F, H), which might be related to
the lower fat mass already observed in TTD fed normally
(Figure 1D) [21]. In parallel, fasting blood lactate levels were
similar between the two lines (Figure 1I) [28], suggesting that
lactate was normally utilized in TTD mice as a major substrate
for glucose synthesis via gluconeogenesis. Finally, insulin and
glucose, at a comparable level at fed state in WT and TTD mice,
were similarly reduced during fasting (Figure 1K and 1L), while
glucagon progressively increased in WT and TTD (Figure 1J). In
parallel, to evaluate the gluconeogenic potential of TTD mice,
pyruvate tolerance tests were undertaken (Figure 1M). After
injection of the gluconeogenic substrate pyruvate, TTD mice
showed significant lower plasma glucose levels at 30, 45, 60 and
80 min, after what they reached the same levels of that observed
in WT mice. Taken together, these data suggest that, although
able to maintain physiological glucose level, TTD mice might
develop subtle gluconeogenic defects upon fasting.
Since the liver plays a central role in gluconeogenesis, we next
focused our investigation on the hepatic response to fasting in
TTD mice. We previously observed no significant difference in the
architecture of the hepatic parenchyma (as revealed after H&E
staining, Figure 1G, sections 1 and 2) between WT and TTD mice
fed normally [21]. However, glycogen content, visualized through
Periodic Acid-Schiff staining (sections 3–8), showed slight prefer-
ential accumulation in pericentral hepatocytes (located around
pericentral veins, CV) of WT mice fed normally (section 3), while
such glycogen accumulation seemed to be more pronounced in
TTD livers (compare sections 3 and 4). As expected, the glycogen
stores were totally depleted in WT and TTD livers after 24 h of
fasting (sections 5 and 6). Afterwards, glycogen was re-accumu-
lated in periportal hepatocytes (located around periportal veins,
PV) during a prolonged fasting period (48 h, sections 7 and 8),
indicating that glucose-6-phosphate was channeled towards
glycogen, as previously observed in rodent livers [28,29].
However, such de novo glycogen accumulation was disorganized
in TTD livers, with a higher number of hepatocytes bearing strong
Author Summary
In eukaryotes, the expression of genes encoding proteins
requires the action of hundreds of factors, together with
the RNA polymerase II. While these factors are timely and
selectively required for the expression of a given gene,
little is known about their partnership upon gene
expression. Our results reveal a cooperation between
different types of transcription factors, namely the general
transcription factor TFIIH, the cofactor PGC-1a and the
deacetylase SIRT1. Such partnership is however impaired
when TFIIH is mutated, as observed in Trichothiodystrophy
patients that develop premature ageing. These results thus
shed light on the coordinated action of factors during
transcription and allow us to better understand molecular
deficiencies observed in many human diseases.
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intracellular glycogen deposits when compared to WT (compare
sections 7 and 8).
Deregulation of gluconeogenic genes in TTD liver
Knowing that PEPCK and G6Pase are two key hepatic
gluconeogenic enzymes required to meet energy demands during
stressful conditions like starvation [3], we analyzed their zonal
distribution in TTD liver. Surprisingly, in normal feeding
conditions immunohistochemical (IHC) staining of PEPCK
showed a higher signal in hepatocytes located around portal vein
(PV) in TTD liver (Figure 2A, sections 1–2). Prolonged fasting
increased the PEPCK protein levels within the hepatic parenchy-
ma, with a persistent higher signal in TTD when compared to WT
(sections 3–4). In parallel, IHC staining of G6Pase revealed a low
signal around central vein (CV) in livers of WT and TTD mice fed
normally (Figure 2B, sections 1 and 2). After 48 h of fasting
Figure 1. Fasting response of WT and TTD mice. (panel A) Daily food intake of WT (black box, n = 6) and TTD (open box, n = 6) mice during 15
days. Measurement of the body (panel B), liver (panel C) and epididymal white adipose tissue (WAT, panel D) weight of WT (black boxes) and TTD
(open boxes) mice fed ad libitum or fasted for 24 h or 48 h. Values for liver weight are percentages relative to the ad libitum weight. Serological levels
of triglycerides (panel E), free fatty acids (panel F), b-hydroxybutyrate (panel H), lactate (panel I), glucagon (panel J), insulin (panel K) and blood
glucose (panel L) in WT (black boxes) and TTD (open boxes) fed normally or fasted for 24 h or 48 h. Error bars represent standard deviations. (panel
M) Pyruvate tolerance tests. WT (solid curves, n = 4) and TTD (dashed curves, n = 4) mice were fasted for 16 h and injected with sodium pyruvate (2 g/
Kg of body weight). The data are means 6 SEM. (panel G) Hematoxylin & Eosin (H&E) staining of liver sections from WT and TTD mice fed normally
(sections 1–2) and Periodic Acid Schiff staining of liver sections from WT and TTD mice fed normally (sections 3–4) and fasted for 24 h (sections 5–6)
or 48 h (sections 7–8). PV = Portal Vein; CV= Central vein. Magnification is indicated at the bottom left of each section. The statistical symbols reflect
significant differences between genotypes (*, p,0.05; **, p,0.01; ***, p,0.001 Student’s t-test).
doi:10.1371/journal.pgen.1004732.g001
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G6Pase protein level raised throughout the liver parenchyma ofWT
mice (section 3), whereas it did not increase in TTD (section 4).
Knowing that the Pepck and G6pase genes are tightly regulated
at a transcriptional level [14], we analyzed the amount of their
corresponding mRNA by quantitative RT-PCR. We repeatedly
observed a higher amount of Pepck mRNA in liver of TTD mice
fed ad libitum when compared to WT (Figure 2C), which mirrored
the protein amount observed by IHC analyses (Figure 2A, sections
1–2); after fasting, the Pepck mRNA amount progressively
increased in WT liver, whereas its accumulation occurred tardily
in TTD liver, which might be related to the fact that basal levels at
the feeding state were higher (Figure 2C). In parallel, the amount
of the G6pase mRNA progressively increased in the liver of WT,
while its accumulation seemed to be delayed in TTD liver
(Figure 2D).
These data prompted us to study the PGC-1a coactivator,
which contributes to the hepatic transcriptional activation of the
Pepck and G6pase genes during starvation [14,15]. Whereas
Western Blot analyses showed an increase of the PGC-1a protein
level in WT and TTD liver after 48 h of fasting (Figure 2E,
compare lanes 7–9 to lanes 1–3 and lanes 10–12 to lanes 4–6,
respectively), quantitative RT-PCR analyses revealed that the
mRNA amount of the fasting-induced Pgc-1a gene was delayed in
TTD liver when compared of that observed in WT (Figure 2F).
Taken together, these data suggest that defective expression of
gluconeogenic genes occurs during fasting in TTD liver.
Defective recruitment of PGC1-a in TTD hepatocytes
To accurately dissect the transcriptional response occurring in
TTD liver during fasting, hepatocytes were immortalized from
WT and TTD mouse embryonic livers and then treated with
medium devoid of glucose and supplemented with pyruvate,
forskolin and glucagon, a treatment (referred for convenience
pyruvate treatment) known to stimulate the gluconeogenic
pathway [15]. Quantitative RT-PCR showed that the Pgc-1a
gene was weakly induced 2 hours post-treatment in TTD
hepatocytes when compared of that observed in WT hepatocytes
(Figure 3A1). The expression of the PGC-1a-dependent Pepck
and G6pase genes was lower and delayed in TTD cells when
compared to their induction in WT hepatocytes (Figure 3B1 and
C1, respectively). Remarkably, transfection of XPDwt in TTD
hepatocytes restored the expression profiles of the Pgc-1a, Pepck
and G6Pase genes similarly to that observed in normal cells
(Figure 3A1, B1 and C1), suggesting that the mutation in the xpd
gene promoted the defective expression of gluconeogenic genes
observed in TTD hepatocytes. It is worthwhile to notice that the
expression of PGC1-a target genes involved in fatty acid
oxidation, such as Cpt1a (Carnitine palmitoyltransferase Ia) and
Mcad (Medium-chain acyl-CoA dehydrogenase) was also disrupt-
ed in TTD hepatocytes (Figure S1A).
Chromatin Immunoprecipitation (ChIP) assays then showed
that RNA pol II and TFIIH (visualized by the presence of its p62
and CDK7 subunits) were recruited 2 hours post-treatment at the
Figure 2. Dysregulation of gluconeogenesis-induced proteins in TTD liver. PEPCK (panel A) and G6Pase (panel B) immunostainings of
liver sections from ad libitum (sections 1–2) and 48 h fasted (sections 3–4) WT and TTD mice. PV = Portal Vein; CV= Central vein. Magnification is
indicated at the bottom left of each part. Expression of the hepatic fasting-induced Pepck (panel C) and G6pase (panel D) genes in WT (black boxes,
n = 4) and TTD (open boxes, n = 4) fed normally or fasted for 24 h or 48 h. Results are expressed as the mean normalized to 18S RNA. (panel E)
Western Blot analyses of PGC-1a (110 kDa) levels in the liver of three WT and three TTD fed normally (lanes 1–6) or fasted for 48 h (lanes 7–12). TBP
(TATA box Binding Protein, 36 kDa) has been used as an internal control. Diagram represents the mean of the ratios between PGC-1a and TBP for
each group. (panel F) Expression of the Pgc-1a gene in WT (black boxes, n = 4) and TTD (open boxes, n = 4) fed normally or fasted for 24 h or 48 h.
Results are expressed as the mean normalized to 18S RNA. Error bars represent standard deviations. The statistical symbols reflect significant
differences between genotypes (**, p,0.01, Student’s t-test).
doi:10.1371/journal.pgen.1004732.g002
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PGC-1a promoter (Figure 3, panels A2 to A4) and 4 h post-
treatment at the PEPCK and G6Pase promoters (panels B2–B4
and C2–C4, respectively) in WT hepatocytes, matching the
expression profile of the corresponding genes. On the contrary,
RNA pol II and TFIIH recruitments were altered and delayed in
TTD hepatocytes. Interestingly, we also noticed that the
Figure 3. Defective recruitments of transcription factors on the promoter of gluconeogenic genes in TTD hepatocytes. Expression of
Pgc-1a (panel A1) Pepck (panel B1) and G6Pase (panel C1) genes in WT (solid curves), TTD (dashed curves) and TTD overexpressing XPDwt (dotted
curves) hepatocytes after pyruvate treatment. The results are presented as n-fold induction relative to non-treated cells. Recruitment of RNA pol II,
p62, CDK7, PGC-1a and SIRT1 on the proximal promoter of PGC-1a (panels A2 to A6), PEPCK (panels B2 to B6) and G6Pase (panels C2 to C6) in
WT (dotted curves) and TTD (dashed curves) hepatocytes. The results of three independent experiments are presented as percentage of DNA
immunoprecipitated relative to the input. The shaded areas underline the concomitant recruitments of the transcription factors with the expression
profile of the target genes in WT hepatocytes. (panel D) Western blot analyses of TFIIH, illustrated by its p62 (62 kDa) and CDK7 (39 kDa) subunits,
PGC-1a (110 kDa) and SIRT1 (110 kDa) with increasing amounts of whole cell extracts isolated from WT (lanes 1–3) and TTD (lanes 4–6) hepatocytes.
b-tubulin (b-Tub, 50 kDa) has been used as an internal control. * indicates unspecific band. Measurement of intracellular glucose 6-phosphate (panel
E) and glucose output (panel F) levels from WT (black boxes) and TTD (open boxes) hepatocytes after 0 and 12 hours of pyruvate treatment. Values
represent the means 6 SEM. The statistical symbols reflect significant differences between genotypes (*, p,0.05, Student’s t-test).
doi:10.1371/journal.pgen.1004732.g003
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recruitment of PGC-1a was disrupted on its own promoter as well
as on that of PEPCK and G6Pase (panels A5, B5 and C5). As a
consequence, the recruitment profiles of transcription factors that
are activated by PGC-1a, such as HNF-4a [9], FOXO1 [30] and
CREB [31], were altered in TTD hepatocytes (Figure S1B). It is
worthwhile to notice that the protein amounts of HNF-4a,
FOXO1 and CREB were similar in WT and TTD hepatocytes
(Figure S1C) and the nuclear localization as well as the acetylation
status of FOXO1 was not disrupted in TTD hepatocytes (Figure
S1D). Finally, the recruitment of the deacetylase SIRT1, which
activates PGC-1a [15], was also disrupted in TTD hepatocytes
(Figure 3, panels A6, B6 and C6). Strikingly, Western Blots
analyses revealed that the PGC-1a and SIRT1 protein amounts
were similar in WT and TTD hepatocytes (Figure 3D), suggesting
that their defective recruitments on the promoter of target genes in
TTD were not due to lower protein amounts. Nonetheless, we also
noticed that the amount of TFIIH subunits (such as p62 and
CDK7) was reduced in TTD cells (Figure 3D) [32].
Taken together, these data show that the expression of PGC-1a
is altered in TTD hepatocytes, resulting in a defective regulation of
PGC-1a-targeted gluconeogenic genes. As a consequence, intra-
cellular glucose 6-phosphate (Figure 3E) and glucose output
(Figure 3F) were reduced in TTD hepatocytes after 12 h of
pyruvate treatment.
Partnerships between TFIIH, PGC-1a and SIRT1
Since TFIIH and PGC-1a have in common the ability to
coactivate some nuclear receptors [22,33,34], and the activation
by the latter requires its deacetylation by SIRT1 [15,16], we
investigated the partnerships that might exist between TFIIH,
SIRT1 and PGC-1a. Having observed that TFIIH mutation
disrupted PGC-1a and SIRT1 recruitment at the promoter of
target genes (Figure 3A5–6, B5–6 and C5–6), we investigated
whether these factors interacted with each other. Antibodies
directed towards PGC-1a co-immunoprecipitated SIRT1 as well
as TFIIH (illustrated by the presence of its p62 subunit) from WT
hepatocytes nuclear extracts (Figure 4A, lane 2). Strikingly, these
co-immunoprecipitations were reduced in TTD hepatocytes
extracts (compare lanes 2 and 4 in Figure 4A). However,
supplementation of TTD nuclear extracts with highly purified
recombinant TFIIH (rIIH) potentiated the binding of SIRT1 to
PGC-1a to a level similar to that observed in WT (Figure 4A,
lanes 4 and 5). In a second set of assays, we observed that rIIH co-
immunoprecipitated with purified PGC-1a (Figure 4B) [35] and
SIRT1 (Figure 4C). PGC-1a specifically interacted with recombi-
nant XPB, p34 and MAT1 subunits of TFIIH (Figure 4D), while
SIRT1 co-immunoprecipitated with XPB, p62, cdk7 and MAT1
(Figure 4E).
PGC-1a acetylation profile was then analyzed in WT and TTD
hepatocytes after pyruvate treatment. Western Blots revealed that
the immunoprecipitated PGC-1a was deacetylated until 6 h post-
treatment in WT hepatocytes (Figure 4F, lanes 1–3) concomitantly
to a higher co-immunoprecipitation of SIRT1 (Figure 4G, lanes
1–3), thereby allowing the recruitment of PGC-1a on targeted
promoters (Figure 3A5, B5 and C5). On the contrary, in TTD
hepatocytes PGC-1a acetylation remained relatively high (Fig-
ure 4F, lanes 5–6), which was in accordance with the lower co-
immunoprecipitation of SIRT1 (Figure 4G, lanes 5–6) and with
the weaker recruitment of PGC-1a on targeted promoters
(Figure 3A5, B5 and C5). Taken together these results show that
PGC-1a and SIRT1 both interact with TFIIH, and suggest that
the reduced amount of TFIIH in TTD hepatocytes affects the
partnership between SIRT1 and PGC-1a and consequently PGC-
1a deacetylation.
Dynamic connection between TFIIH, PGC-1a and SIRT1
The connection between TFIIH, PGC-1a and SIRT1 was
further investigated. We first evaluated whether the acetylation
status of PGC-1a influenced its interaction with TFIIH and
SIRT1 (Figure 5A). Non acetylated and acetylated PGC-1a were
immunoprecipitated from WT hepatocytes and were incubated
with SIRT1 and recombinant TFIIH (rIIH). Our results revealed
that SIRT1 as well as TFIIH (illustrated by the presence of its p62
subunit) were able to co-immunoprecipitate with PGC-1a
regardless of its acetylation status (lanes 2 and 4). Furthermore,
addition of a specific SIRT1 inhibitor (EX-527, 10 mM) [36,37]
did not affect the TFIIH/PGC-1a/SIRT1 complex, whichever
the PGC-1a acetylation status (lanes 3 and 5).
Having observed that TFIIH (via its CDK7 kinase subunit)
phosphorylated in vitro SIRT1 and not PGC-1a (Figure 5B),
recombinant TFIIH containing wild-type XPD subunit (rIIH-
XPD/WT) was immunoprecipitated (with antibodies directed
against the XPB subunit) and incubated with SIRT1 and/or PGC-
1a in the presence or absence of 100 nM ATP (Figure 5C). We
firstly noted that the interaction between SIRT1 and rIIH XPD/
WT was not modified upon addition of either ATP (lane 4) or a
CDK7 kinase inhibitor (CDK7 inh., lane 5), suggesting that the
CDK7-mediated phosphorylation of SIRT1 did not influence its
binding to TFIIH. On the contrary, addition of ATP disrupted the
interaction of PGC-1a to rIIH XPD/WT (lanes 6–7). While the
presence of PGC-1a potentiated the binding of SIRT1 to the
immunoprecipitated rIIH XPD/WT (lane 8), we observed that
addition of ATP promoted the release of PGC-1a and therefore of
SIRT1 (lane 9). Such effect was not related to the CDK7 kinase
activity, since the addition of CDK7 inhibitor did not affect the
release of SIRT1 as well as of PGC-1a (lane 10).
Knowing that the TTD mutated form XPD/R722W affects the
integrity of TFIIH by weakening the binding of the CAK
subcomplex to the core of TFIIH [18,38], we next evaluated the
consequences of such mutation on the TFIIH/SIRT1/PGC-1a
complex formation (Figure 5D). Whereas the binding of SIRT1
alone to the immunoprecipitated rIIH XPD/R722W was not
modified even in presence of ATP (lane 3–5), we observed that
ATP modulated the binding of PGC-1a (lanes 7 and 9).
Furthermore, contrary to that observed with rIIH XPD/WT,
the binding of SIRT1 to rIIH XPD/R722W was not enhanced by
the presence of PGC-1a (lane 8), suggesting that the integrity of
TFIIH is crucial for the optimal binding of SIRT1.
The core of TFIIH without XPD and the CAK subcomplex
(core-IIH no XPD) was then immunoprecipitated using antibodies
directed against XPB, and incubated with SIRT1 and/or PGC-1a
(Figure 5E). Although SIRT1 and PGC-1a bound the core-IIH
(lanes 3 and 6, respectively), the binding of PGC-1a in the
presence of SIRT1 was reduced when compared to that observed
with rIIH XPD/WT (Figure 5C, lane 8), suggesting that XPD and
the CAK subcomplex are required for accurate binding of PGC-
1a. In parallel, the binding of SIRT1 to the core-IIH was not
strongly potentiated by the presence of PGC-1a (lane 8).
Interestingly, while ATP promoted the release of PGC-1a from
the immunoprecipitated complex (lane 7), it did not modify the
binding of SIRT1 (lane 4), suggesting that the ATP-dependent
release of PGC-1a did not involve the CAK subcomplex.
Furthermore, non-hydrolysable ATP analog (ATP-cS, 100 nM)
promoted the release of PGC-1a (and therefore of SIRT1) from
the core-TFIIH (lane 10).
Having noticed that both PGC-1a and SIRT1 interacted with
the XPB ATP-binding subunit of TFIIH (Figure 4D and 4E,
respectively), we incubated these three proteins in the presence of
ATP (Figure 5F). After immunoprecipitation of XPB, we observed
Dynamic Partnership between TFIIH, PGC-1a and SIRT1
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that ATP promoted the release of PGC-1a (lanes 6) without
affecting the binding of SIRT1 (lane 4). Our data prompted us to
immunoprecipitate a mutated form of XPB that does not bind
ATP (XPB/K346R, Figure 5G) [39,40,41]. While SIRT1 and
PGC-1a interacted with this mutated form of XPB (lanes 3 and 5,
respectively), no release of PGC-1a was observed in the presence
of ATP (lane 6). Taken together, these results suggest that the
binding of ATP to XPB influences the PGC-1a release without
affecting the interaction with SIRT1.
Discussion
The production of glucose during fasting requires an extensive
use of metabolites, including lactate, amino acids, triglycerides and
ketone bodies. Although serological analyses from fasted TTD
mice revealed slight reductions when compared to WT for
triglycerides, free fatty acids and ketones bodies (Figure 1E, F, H)
[21], TTD mice seemed to be able to cope with prolonged fasting
periods by maintaining glucose at a level similar to that observed
Figure 4. TFIIH influences PGC-1a deacetylation by SIRT1 by interacting with both. (panel A) After immunoprecipitation of PGC-1a from
nuclear extracts of WT (lanes 1–2) and TTD (lanes 3–5) hepatocytes, co-immunoprecipitated proteins were visualized by western blots with antibodies
raised against PGC-1a (110 kDa), SIRT1 (110 kDa) and the p62 subunit (62 kDa). TTD nuclear extract was supplemented with recombinant TFIIH (rIIH,
lane 5). (panel B) When indicated (+), GST-PGC-1a purified from bacteria (130 kDa) was incubated with lysate of Sf9 cells overexpressing TFIIH (rIIH).
After immunoprecipitation with an anti Flag-Tag antibody (that recognized the flagged XPB subunit, 89 kDa), the bound proteins were visualized by
western blots using antibodies raised against PGC-1a and XPB. (panel C) Purified SIRT1 (110 kDa) was incubated with lysate of Sf9 cells
overexpressing TFIIH (rIIH). Immunoprecipitations were performed as described panel B. The bound proteins were visualized by western blots using
antibodies raised against SIRT1 and XPB. (panel D) In vitro pull-down assays were performed with GST alone (-, 26 kDa, lanes 2) or GST-PGC-1a (PGC-
1a, 130 kDa, lanes 3) incubated with Sf9 cell extracts overexpressing separately each subunit of TFIIH. The bound proteins were visualized by western
blots using antibodies directed against each TFIIH subunit. As a reference, the input lanes (IN, lanes 1) represent 10% of the total volume of extract
used for each incubation. (panel E) Purified SIRT1 was incubated with Sf9 cell extracts overexpressing separately each TFIIH subunit.
Immunoprecipitations (IP) were done using antibodies directed against the TFIIH subunits. The bound proteins were revealed by western blots.
(panel F) Deacetylation profile of PGC-1a in WT (lanes 1–3) and TTD (lanes 4–6) hepatocytes after different times of pyruvate treatment (0, 4 and
6 hours). After immunoprecipitation with specific antibodies (IP Ab-PGC-1a), PGC-1a acetylation has been visualized by western blots with anti-acetyl
lysine antibodies. Graph depicts the ratio of acetyl-Lysine (Ac-Lys)/PGC-1a western blots signals. (panel G) PGC-1a was immunoprecipitated with
specific antibodies (IP Ab-PGC-1a) from nuclear extracts of WT (lanes 1–3) and TTD (lanes 4–6) hepatocytes after different times of pyruvate treatment
(0, 4 and 6 hours). Co-immunoprecipitated proteins were visualized by western blots with anti-PGC-1a and -SIRT1 antibodies. Graph depicts the
binding ratio between SIRT1 and PGC-1a.
doi:10.1371/journal.pgen.1004732.g004
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in normal mice (Figure 1L). However, such maintenance in front
of a stressful condition resulting from food deprivation was
accompanied by failures in the liver. In particular, disruption was
quickly observed during pyruvate tolerance tests (Figure 1M),
which implies defects in the liver and certainly in other peripheral
tissues, such as the adipose tissues. Defect in different metabolic
processes might be implicated, such as lipid uptake, mitochondrial
function and gluconeogenic pathway. Furthermore, the de novo
hepatic accumulation of glycogen occurring after longer fasting
period was also disrupted in TTD (Figure 1G). Although the
gluconeogenic enzymes defects observed in TTD livers (Figure 2)
might contribute to the glycogen accumulation abnormalities,
Figure 5. Dynamic partnership between TFIIH, PGC-1a and SIRT1. (panel A) SIRT1 and TFIIH bind to PGC-1a independently to its acetylation
status. After immunoprecipitation with specific antibodies (IP Ab-PGC-1a), non acetylated (PGC-1a, lanes 2–3) and acetylated PGC-1a (Ac-PGC-1a,
lanes 4–5) were incubated with purified SIRT1 and recombinant TFIIH (rIIH). When indicated (+), specific SIRT1 inhibitor (SIRT1 inh., 10 mM) was also
added. Co-immunoprecipitated proteins were visualized by western blots with anti-PGC-1a, -acetyl-Lysine, -p62 and -SIRT1 antibodies. (panel B) In
vitro phosphorylation of SIRT1. When indicated (+), GST-C-terminal domain of the largest subunit of the RNA pol II (GST-CTD, 90 kDa) (used as positive
control, lanes 1–2) [53], PGC-1a (130 kDa, lanes 3–4) and SIRT1 (110 kDa, lanes 5–6) were incubated with recombinant TFIIH (rIIH) in the presence of
[c-32P] ATP and CDK7 inhibitor (CDK7 inh.). Coomassie blue staining gel (top panels) and autoradiography (bottom panels) of the incubated fractions
are shown. (panels C–G) When indicated (+), SIRT1 (110 kDa), PGC-1a(130 kDa, ATP (100 nM), CDK7 inhibitor (CDK7 inh.) and non-hydrolyzable ATP
analog (ATP-cS, 100 nM) were incubated with either immunoprecipitated recombinant TFIIH with WT XPD subunit (rIIH XPD/WT, panel C),
recombinant TFIIH with mutated XPD (rIIH XPD/R722W, panel D), core-TFIIH without XPD (panel E), XPB subunit (panel F) or mutated XPB bearing
the point mutation K346R (XPB/K346R, panel G). Co-immunoprecipitated proteins were visualized by western blots using anti-SIRT1, -PGC-1a, -p62
and -XPB antibodies. Graphs depict the binding of PGC-1a and SIRT1.
doi:10.1371/journal.pgen.1004732.g005
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further investigations should be performed in order to claim such
assertion.
To maintain blood glucose levels in conditions of food
deprivation, a precise regulation of the hepatic genes that control
glucose production is required. However, the accurate and timely
expression of the gluconeogenic genes Pepck and G6pase was
clearly disrupted in TTD liver (Figure 2C, D), which can therefore
explain the abnormal amount of PEPCK and G6Pase observed
after fasting (Figure 2A, B). Although the phenotypes observed in
TTD might result from pleiotropic effects due to the dysfunctions
of various transcription factors, the deregulation of the gluconeo-
genic genes seems at least in part to concern PGC-1a, a
coactivator whose induction is also delayed in fasted TTD
(Figure 2F), and this raises the question on the role of the mutated
TFIIH in such defect. By weakening the overall structure of
TFIIH and its cellular concentration (Figure 3D) [18,38], it seems
that the XPD/R722W mutation prevents the capacity of TFIIH to
correctly interact with PGC-1a and SIRT1 (Figure 4A and 5C)
and to promote the PGC-1a deacetylation by SIRT1 (Figure 4F).
Thus, PGC-1a recruitment is impaired on the promoter of
PEPCK and G6Pase (Figure 3 B5 and C5, respectively), having as
a consequence the alteration of the concomitant recruitment of
transcription factors such as HNF-4a, FOXO1 and CREB (Figure
S1B). Besides the fact that the integrity of TFIIH is essential for the
PGC-1a coactivation function, the partnership of TFIIH with
SIRT1 and PGC-1a also requires an ATP-dependent dynamic
process via the XPB subunit (Figure 5F). Interestingly, the helicase
XPB subunit is known to harbor conformational change in the
presence of DNA, which is facilitated by ATP hydrolysis, leading
to a closed and stable XPB/DNA complex [41,42]. It seems
increasingly clear that conformational changes in XPB resulting
from the binding and/or the hydrolysis of ATP would allow new
connections with DNA and proteins.
Taken together, our observations highlight the fine and dynamic
relationships that exist between the basal transcription machinery,
the transcription factors and their cofactors, which allow the
expression of protein coding genes at the right time and in the right
amount. Previous studies showed that TFIIH participates to the
transactivation mediated by different nuclear receptors by phos-
phorylating them [21,22,43]. Interestingly, the CDK7 kinase
subunit of TFIIH also phosphorylates SIRT1 but not PGC-1a, at
least in vitro (Figure 4A). Whereas the analysis of truncated forms of
SIRT1 suggested that the catalytic and the C-terminal part of
SIRT1 might be phosphorylated by the CDK7 kinase, we failed to
identify the targeted residues. Interestingly, different phosphorylat-
ed sites have been already found in SIRT1 [44], some of them
promoting the deacetylation activity of SIRT1 [45]. Although the
role of the SIRT1 phosphorylation by TFIIH is far from being
established (Figure 6), the finding of a dynamic connection between
TFIIH and SIRT1 remains particularly relevant, since SIRT1 plays
a critical role in health maintenance and metabolic stress responses
[46,47]. In particular, it has been shown that, while the
accumulation of DNA damage caused by oxidative stress contrib-
utes to human tissue ageing, strong evidence supports a role for
SIRT1 in oxidative stress response by deacetylating transcription
factors that regulate the expression of stress response genes [48,49].
Furthermore, recent data suggest that the transcriptional arrest
following UV irradiation in cells bearing XPD mutations associated
to the combined XP/CS syndrome results from an active and
persistent heterochromatinization process mediated by SIRT1 [50].
Therefore, in addition to further understand the synergistic action of
factors during gene expression, our results allow us to better
apprehend the etiology of human diseases during which transcrip-
tional mechanisms may be impaired.
Materials and Methods
Ethic statement
This study was performed with the agreement of the French
Ministry of Higher Education and Research (permit number
nu6754). Furthermore, our study has been followed by the Ethical
committee of the Institute, which is registered by the French
National Committee for Ethics in Animal Experimentation nu17.
This study has been realized in the accredited animal house of the
Institute, in compliance with European guidelines. Euthanasia
using carbon dioxide has been realized on adult mice. Every effort
was made to minimize suffering.
Animal studies
The generation of the TTD mouse line XPD/R722W has been
previously described [24]. Three-month-old WT and TTD males
used in our experiments share identical genetic background (100%
C57BL/6) and are littermates. Mice were either fed a standard
chow with 5% (w/w) fat content (R03 breeding diet, UAR,
Villemoisson, France) or fasted for the indicated periods. For
histological analyses, liver fragments were fixed in 4% formalde-
hyde for 24 h prior to paraffin embedding. Liver sections were
5 mm thick, and were stained according to the European Mouse
Phenotyping Resource of Standardised Screens (http://www.
eumorphia.org). Liver fragments were also frozen for RNA and
proteins extraction. Blood glucose levels were measured with One
Touch Ultra Glucose meter (LifeScan Inc, Milpitas, California).
Triglycerides, free fatty acids and b-hydroxybutyrate measurement
from serum were performed with an OLYMPUS AU-400
automated laboratory workstation. Insulin and glucagon were
measured using Millipore Milliplex Kit and Glucagon quantikine
Elisa kit (R&D Systems Europ), respectively. Lactate and Pyruvate
levels were measured using Abcam kits ab65331 and ab65342,
respectively. For the Pyruvate Tolerance Tests, overnight fasted
(16 h) mice were injected IP with pyruvate (2 g/kg), and the
glucose level was measured before and after injection at the
different time points.
Immunohistochemistry
Immunostainings on liver sections (5 mm) were performed using
polyclonal anti-G6Pase (ab83690, Abcam) and anti-PEPCK (sc-
74823, Santa Cruz) antibodies. As secondary antibody, Alexa
Fluor Goat Anti-Rabbit IgG (Invitrogen) diluted 1:200 was used.
Counterstaining was performed with DAPI.
Cell culture and reagents
Hepatocytes were isolated from liver tissues derived from E14.5-
murine WT and TTD embryos as previously described [51,52].
After careful selection, WT and TTD hepatocytes were grown in
Dulbecco’s modified Eagle medium (DMEM) containing 10% of
fetal calf serum (FCS), 40 mg/ml gentamicin, 1x nonessential
amino acid solution (Fischer Scientific), 2 mM L-glutamine
(Invitrogen), 1x Insulin-Transferin-Selenium solution (ITS, Invi-
trogen), 0,1 mg/ml dexamethasone (Sigma Aldrich) and antibiot-
ic/antimycotic solution (Invitrogen). Before stimulation of the
gluconeogenesis pathway, cells were preincubated with 1 g/l
glucose and red phenol-free medium containing 2,5% charcoal
treated FCS and ITS for 16 hr. Hepatocytes were then treated in
absence of glucose with 1 mM pyruvate, 10 mM Forskolin (Sigma
Aldrich) and 150 nM glucagon (Sigma Aldrich). 16106 harvested
cells were used to measure intracellular Glucose 6-Phosphate and
NAD and NADH levels (using Abcam assay kits ab83426 and
ab65348, respectively). Glucose output in the medium was
measured with glucose assay kit (Abcam ab65333). Hepatocytes
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were transiently transfected with 1 mg of PGC-1a expression
vector using the transfection reagent JetPEI (Polyplus Transfec-
tion); the cells were harvested at 72 h posttransfection. To
potentiate the PGC-1a acetylation, WT hepatocytes were
cotransfected with p300 and treated with nicotinamide (10 mM)
for 16 h before harvesting [16].
Retrotranscription and real-time quantitative PCR
Total RNAs (2 mg) were reverse-transcribed with Moloney
murine leukemia virus RT (Invitrogen) using random hexanucleo-
tides. Real-time quantitative PCR was done using the ‘‘FastStart
DNA Master SYBR Green’’ kit and the Lightcycler apparatus
(Roche Diagnostic). The mRNA levels of interest were normalized
to the 18S RNA amount, which was not affected by the different
fasting periods (in the liver) and the pyruvate treatment (in the
hepatocytes).
Chromatin Immunoprecipitation (ChIP)
ChIP experiments were performed as previously described [21].
Primers were designed to amplify the proximal promoter region of
PEPCK (2300 to +13), G6Pase (2122 to +54) and PGC1a (2134
to +19).
Antibodies
Monoclonal antibodies against the TFIIH subunits, RNA pol II,
GST-Tag and Flag-Tag were produced at the IGBMC. Antibod-
ies against PEPCK (sc-74823, Santa Cruz SC), G6Pase (Ab83690,
AB Cam LTD), PGC-1a (4C1.3, Calbiochem; AB3242, Milli-
pore), SIRT1 (2028, Cell Signaling Technology CST and 3H10.2
Millipore, for murine and human SIRT1, respectively), HNF-4a
(C-19, SC), FOXO1 (L27, CST), acetylated FOXO1 (D-19, SC),
CREB (48H2, CST), b-tubulin (KMX-1, Millipore) and acetylated
lysine (9441, SCT) were purchased.
Plasmids and construction of PGC-1a and SIRT1
Full-length human SIRT1 and mouse PGC-1a were obtained
from Addgene (plasmid #13735 and #1026, respectively). Flag-
PGC-1a was overexpressed and immunoprecipitated from cells.
Truncated PGC-1a (36-797 amino acids, for solubility reasons)
[33], was cloned into the bacterial expression vector pGEX-4T3
and purified via the GST-Tag to perform in vitro analyses.
In vitro kinase assays
His-SIRT1, GST-PGC-1a and GST-CTD proteins were
produced in E. Coli strain BL21 and purified on either NI-NTA
agarose (Qiagen) or glutathione column (Thermo Scientific). Equal
amounts (1 mg) of recombinant proteins were incubated with
highly purified TFIIH (rIIH) in the presence of [c-32P] ATP
(0.14 mM).
Co-immunoprecipitation assays
Sf9 cells were infected with baculoviruses encoding either each
Flag-subunit of TFIIH separately or all subunits together to
produce an entire TFIIH. Whole extracts from infected cells were
incubated with antibody against the Flag-Tag to immunoprecip-
itate either the entire TFIIH (containing only the Flag-tagged XPB
subunit) or each Flag-tagged subunit individually. After incubation
with His-SIRT1 and/or GST-PGC-1a during 2 h at 4uC and
extensive washings (400 mM KCl), bound protein were resolved
by SDS-PAGE and revealed by immunoblotting.
Supporting Information
Figure S1 (panel A) Expression of Cpt1a (Carnitine palmitoyl-
transferase Ia) and Mcad (Medium-chain acyl-CoA dehydroge-
nase) genes in WT (solid curves) and TTD (dashed curves)
hepatocytes after pyruvate treatment. The results are presented as
n-fold induction relative to non-treated cells. (panel B) Recruit-
ment of HNF-4a, FOXO1 and CREB on the proximal promoter
of PGC-1a (left column), PEPCK (middle column) and G6Pase
(right column) in WT (dotted curves) and TTD (dashed curves)
hepatocytes. The results are presented as percentage of DNA
immunoprecipitated relative to the input. (panel C) Western blot
analyses of HNF-4a, FOXO1 and CREB with increasing amounts
of whole cell extracts isolated from WT (lanes 1–3) and TTD
(lanes 4–6) hepatocytes. b-tubulin (b-Tub, 50 kDa) has been used
as an internal control. (panel D) Whole cell (WCE) and nuclear
(NE) extracts isolated from WT (lanes 1–3) and TTD (lanes 4–6)
hepatocytes were used to analyse by western blots the acetylated
form of FOXO1 and its nuclear translocation after 0, 6 and 12 h
of pyruvate treatment. TBP (36 kDa) has been used as an internal
control.
(TIF)
Figure 6. Model of the dynamic partnership between TFIIH, PGC-1a and SIRT1. SIRT1 and PGC-1a physically interact with various subunits
of the TFIIH complex: SIRT1 interacts with XPB, p62, cdk7 and MAT1, while PGC-1a interacts with XPB, p34 and MAT1. SIRT1 binds to TFIIH alone, but
its interaction is reinforced by the presence of PGC-1a. The simultaneous interaction between TFIIH, PGC-1a and SIRT1 suggests that TFIIH might
contribute to the PGC-1a deacetylation by SIRT1. Such assumption is supported by the fact that i) the integrity of TFIIH is crucial for the optimal
binding of PGC-1a and SIRT1 and ii) the PGC-1a deacetylation is disrupted by XPD mutation (such as XPD/R722W) that affects the integrity of TFIIH. In
parallel, the CDK7 kinase of TFIIH targets SIRT1, but the function of such phosphorylation(s) remains elusive. Finally, the binding of ATP to the XPB
subunit of TFIIH influences the release of PGC-1a, which in turn affects the binding of SIRT1.
doi:10.1371/journal.pgen.1004732.g006
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